We are excited to be "exhibiting" at this year's virtual ERS International Congress where we are also presenting 4 clinical posters. The virtual congress takes place from 7 September - 9 September. If you are attending, please visit our Industry Profile Page by clicking on the link below.
CLINICAL POSTERS
The Impact of different Valved Holding Chambers (VHCs) on Lung Drug Delivery: Using Functional Respiratory Imaging (FRI) and a single Metered Dose Inhaler (MDI) type
Conclusions:
- The FRI deposition profiles highlighted significant differences between the VHCs on test, with intrathoracic delivery for the AeroChamber Plus* Flow-Vu* VHC system being almost double that of the other two VHC systems and being similar to the MDI alone with perfect coordination.
- When a short 0.5 second inhalation delay with the MDI alone was modelled, the intrathoracic lung delivery decreased from 25.4 mcg to 0.3 mcg
- These results highlight that the use of an appropriate VHC should be considered as general practice for all MDI patients other than those with a highly proficient inhaler technique and that VHCs should not be considered interchangeable
How can time to COPD exacerbation be delayed? A Real-World Study Comparing Two Oscillating Positive Expiratory Pressure (OPEP) Devices in Patients with Chronic Obstructive Pulmonary Disease (COPD) or Chronic Bronchitis
Conclusions:
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on an In-Vitro Drug Delivery Model
Conclusions:
From a UK perspective, BUD/F delivered via an MDI + VHC offers an economic benefit for the treatment of patients with mild asthma. Further analysis is required to determine if there would be any quality-adjusted life-year (QALY) effects based on the chosen intervention.
Patient centered development of a new valved holding chamber (VHC) designed specifically for on-the-go use.
Conclusions:
The continuous involvement of patients resulted in a number of key insights that helped guide the design process, resulting in the development of a chamber that patients are much more likely to use while on-the-go.